|
Mean (SD) Plasma Cefprozil
Concentrations ( g/ mL) Population Dose 1 h 2 h 4 h 6 h T 1/ 2 (h)
children 7.5 mg/ kg 4.70 3.99 0.91 0.23 a 0.94
(n = 18) (1.57) (1.24) (0.30) (0.13) (0.32)
adults 250 mg 4.82 4.92 1.70 b 0.53 1.28
(n = 12) (2.13) (1.13) (0.53) (0.17) (0.34) children 15 mg/ kg 10.86 8.47 2.75 0.61 c 1.24
(n = 19) (2.55) (2.03) (1.07) (0.27) (0.43)
adults 500 mg 8.39 9.42 3.18 d 1.00 d 1.29
(n = 12) (1.95) (0.98) (0.76) (0.24) (0.14) Text Continues Below
children 30 mg/ kg 6.69 17.61 8.66 --2.06
(n = 10) (4.26) (6.39) (2.70) (0.21)
adults 1000 mg 11.99 16.95 8.36 2.79 1.27
(n = 12) (4.67) (4.07) (4.13) (1.77) (0.12) a n = 11; b n = 5; c n = 9; d n = 11.
Microbiology Cefprozil has in vitro activity against a broad range of gram-positive and gram-negative bacteria. The bactericidal action of cefprozil results from inhibition of cell-wall synthesis. Cefprozil has been shown to be active against most strains of the following microorgan-isms both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic gram-positive Aerobic gram-negative microorganisms: microorganisms: Staphylococcus aureus (including Haemophilus influenzae
-lactamase-producing strains) (including -lactamase-NOTE:
Cefprozil is inactive against producing strains)
methicillin-resistant staphylococci. Moraxella (Branhamella)
Streptococcus pneumoniae catarrhalis (including -Streptococcus
pyogenes lactamase-producing strains) The following in vitro data are available; however, their clinical significance is unknown. Cefprozil exhibits in vitro minimum inhibitory concentrations (MICs) of 8 µg / mL or less against most ( 90%) strains of the following microorganisms; however, the safe-ty and effectiveness of cefprozil in treating clinical infections due to these microorgan-isms have not been established in adequate and well-controlled clinical trials. Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|
.gif)
